Syndax Pharmaceuticals (SNDX) Profit After Tax (2015 - 2026)

Syndax Pharmaceuticals' Profit After Tax history runs 12 years deep, the most recent figure standing at -$42.7 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 49.71% year-over-year to -$42.7 million in Q1 2026; TTM through Mar 2026 was -$243.2 million, a 26.56% increase from a year earlier, with the FY2025 full-year figure at -$285.4 million, up 10.46% from the prior year.
• Profit After Tax improved to -$42.7 million in Q1 2026 per SNDX's latest filing, from -$68.0 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$35.4 million in Q3 2022 and bottomed at -$94.2 million in Q4 2024.
• The 5-year median for Profit After Tax is -$60.7 million (2025), against an average of -$59.1 million.
• Across the five-year window, Profit After Tax plunged 139.03% in 2022 and surged 49.71% in 2026, its largest moves.
• Year by year, Profit After Tax stood at -$37.5 million in 2022, then slumped by 93.97% to -$72.8 million in 2023, then dropped by 29.31% to -$94.2 million in 2024, then climbed by 27.77% to -$68.0 million in 2025, then soared by 37.26% to -$42.7 million in 2026.
• Per Business Quant, the three latest SNDX Profit After Tax figures stand at -$42.7 million (Q1 2026), -$68.0 million (Q4 2025), and -$60.7 million (Q3 2025).